APA (7th ed.) Citation

Song, Y., Ma, J., Zhang, H., Xie, Y., Peng, Z., Shuang, Y., . . . Zhu, J. (2025). Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma. Nature Communications, 16(1), 1. https://doi.org/10.1038/s41467-025-59461-3

Chicago Style (17th ed.) Citation

Song, Yuqin, et al. "Tifcemalimab as Monotherapy or in Combination with Toripalimab in Patients with Relapsed/refractory Lymphoma." Nature Communications 16, no. 1 (2025): 1. https://doi.org/10.1038/s41467-025-59461-3.

MLA (9th ed.) Citation

Song, Yuqin, et al. "Tifcemalimab as Monotherapy or in Combination with Toripalimab in Patients with Relapsed/refractory Lymphoma." Nature Communications, vol. 16, no. 1, 2025, p. 1, https://doi.org/10.1038/s41467-025-59461-3.